Sector News

Horizon is world leader in gene-editing with Sage buy

October 1, 2014
Life sciences
The UK’s Horizon Discovery is acquiring Sage Labs of the USA in a deal which it says will create “the world’s leading gene-editing and translational genomics company”.
 
The Cambridge-headquarted group is paying up to $48 million ($16 million in cash and $32 million in new shares) for Sage, described as “a world leader in the generation of advanced in vivo transgenic disease models for use in preclinical research”. It builds upon the $8 million acquisition of CombinatoRx in July and Horizon says it is now the “go-to company for the provision of integrated product, service and research solutions at all stages of translational genomics and personalised medicine research from sequence to treatment”.
 
Sage belonged to Sigma-Aldrich before a buy-out in 2013 and has 50 employees, a direct US and European sales force and 43,000 square feet state-of-the-art facilities. This will enable the scale-up of Horizon’s product and service offerings “through access to new capabilities, capacity and access to new markets”.
 
David Smoller, Sage chief executive who will now become Horizon’s chief business officer, said the new firm “is now the destination for researchers and scientists worldwide to find both in vivo and in vitro solutions to their biological questions”.
 
By Kevin Grogan
 
Source: Pharma Times

Related News

September 18, 2020

Eli Lilly, Amgen join forces to scale production of COVID-19 antibody cocktails

Life sciences

Months of fervid research have whittled away most potential options to treat patients with COVID-19, a group of antibody cocktails still hold promise. Eli Lilly believes so strongly in its contender that it’s […]

September 16, 2020

Takeda unveils new Boston R&D manufacturing center for cell therapy pipeline push

Life sciences

Japanese drugmaker Takeda has trumpeted its plan in recent years to cut billions of dollars in costs and pivot around oncology and rare diseases. A key part of that strategy […]

September 15, 2020

AstraZeneca, Oxford restart stalled COVID-19 test as Pfizer ramps up trial numbers for its vaccine

Life sciences

Just under a week after it stopped its key phase 3 pandemic vaccine test, AstraZeneca and the University of Oxford have been given the green light to restart in the […]